The ITN’s ACCEPTOR study (Post-transplant Cyclophosphamide) in kidney transplant is now open for enrollment at Johns Hopkins University. The ACCEPTOR study, led by Lode Swinnen, MD, Ephraim Fuchs, MD, and Robert Montgomery, MD (Johns Hopkins Hospital) will combine hematopoietic stem cell (HSC) and kidney transplants as a means to potentially promote tolerance to the donor kidney.
The ITN’s AVATARS study in ANCA-associated Vasculitis (AAV) opened for enrollment today at the University College London. The AVATARS study (Defining Immune Tolerance in ANCA-associated Vasculitis) led by Alan Salama, MD, PhD (University College London) and Peter Merkel, MD (University of Pennsylvania) is a non-interventional, prospective study that will collect blood specimens from patients with AAV with the goal of identifying biomarkers of tolerance.
ITN Type 1 Diabetes Roundup at the International Diabetes Federation (IDF) and Immunology of Diabetes Society (IDS) Meetings
The International Diabetes Federation (IDF) annual meeting (December 2-6, 2013) and Immunology of Diabetes Society (IDS) annual meeting (December 7-11, 2013) in Australia will feature multiple talks on recent findings from the Immune Tolerance Network's ( ITN’s) portfolio of type 1 diabetes studies. Type 1 diabetes is a challenging disease where so far no therapeutic has been able to reverse or permanently halt the autoimmune attack on pancreatic β-cells.
Data from ITN Lupus Nephritis Study to be presented at Upcoming Rheumatology and Nephrology Conferences
Clinical data from the ITN’s ACCESS study (Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis) will be presented at two upcoming conferences. The ACCESS study examined whether the combination of abatacept (CTLA4-Ig) and cyclophosphamide is able to better induce tolerance compared to the Euro-Lupus regimen (low-dose pulse cyclophosphamide).
The Immune Tolerance Network (ITN) is retiring ITN BioShare. ITN’s inventory of clinical trial biospecimens is now available through ITN TrialShare. Now that ITN’s biorepository is accessible through TrialShare, all web traffic to BioShare will redirect to www.ITNTrialShare.org.
Encouraging results from the T1DAL study (Targeting effector memory T cells with alefacept in new onset type 1 diabetes), led by Dr. Mark Rigby (Indiana University) are published today in The Lancet Diabetes & Endocrinology.
It is with great sadness that we report the passing of Lloyd Mayer, MD.
Results from the START clinical study (Study of Thymoglobulin to Arrest Newly Diagnosed Type 1 Diabetes), led by Dr. Steve Gitelman (University of California, San Francisco) with the Immune Tolerance Network (ITN), were published in an article today in The Lancet Diabetes & Endocrinology. The study enrolled 58 new-onset type 1 diabetic subjects ages 12-35.
ITN TrialShare Sees Public Usage Rise Following Publication of the First Manuscript with Embedded Links to the System
In an article reporting the 18-month results of the Immune Tolerance Network’s (ITN) RAVE clinical trial, published August 1st in the New England Journal of Medicine, the ITN is providing unfettered access to the underlying clinical data and analysis code via the new clinical trials research portal, ITN TrialShare (itntrialshare.org).
ITN Achieves Scientific Manuscript First - Provides Open, Interactive Access to Clinical Trial Data with New Publication: Rituximab Therapy Effective for ANCA-associated Vasculitis
In an article reporting the 18-month results of the Immune Tolerance Network’s (ITN) RAVE clinical trial, published August 1st in the New England Journal of Medicine, the ITN is providing unfettered access to the underlying clinical data and analysis code via the new clinical trials research portal, ITN TrialShare